联合多重方法预防卵巢过度刺激综合征的研究

Abstract
Figure/Table
References (21)
Related Citation (1)

Download: PDF (690 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the efficacy of combined multiple methods in preventing ovarian hyperstimulation syndrome during the in vitro fertilization-embryo transfer (IVF-ET) cycles. Methods From January 1st, 2016 to December 31st, 2017, a total of 120 OHSS high-risk patients with IVF-ET in Zhongnan Hospital of Wuhan University were included in the multi-method prevention group. In addition to the selective cryopreservation of embryos, calcium gluconate, cabergoline, infusion of albumin, GnRH antagonists and other methods were added in luteal phase. In addition, 95 high-risk OHSS patients who underwent IVF-ET from January 1st, 2014 to December 31st, 2015 were included in the control group. The primary outcome measure was the incidence of OHSS, and the secondary outcome measure was the days needed to relieve symptoms. Results The incidence of severe OHSS in control group and experimental group was 6.3%(6/95) and 0.8% (1/120), respectively. There was a significant difference between the two groups (P < 0.05). The days required for remission of signs in severe OHSS patients in the control group and experimental group were (6.8±2.1) and (5.4±1.8) d, respectively, and there was a statistically significant difference between the two groups (P < 0.05). However, there was no statistically significant difference in days needed to relieve symptoms of mild OHSS patients (P > 0.05). Conclusion The combination of multiple methods to prevent ovarian hyperstimulation syndrome is scientific and effective, which provides a powerful guide for the prevention of OHSS in IVF-ET.

Key words： Ovarian hyperstimulation syndrome Multiple pathways Incidence Symptom remission

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Hong

Cite this article:

CHEN Hong. Study of combined multiple methods to prevent ovarian hyperstimulation syndrome[J]. 中国医药导报, 2018, 15(27): 74-77.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I27/74

[1] 刘风华，杨业洲，张松英，等.辅助生殖技术并发症诊断及处理共识[J].生殖与避孕，2015，35（7）：431-439.
[2] Busso C Fernández-SánchezM，García-Velasco JA，et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients：arandomized，double-blind，placebo-controlledtrial[J]. Hum Reprod，2010，25（4）：995-1004.
[3] 陈士岭，宋华东，孙玲，等.Coasting 疗法对体外受精-胚胎移植治疗结局的影响[J].中国实用妇科与产科杂志，2007，23（7）：530-532.
[4] 任建枝，沙爱国，李萍，等.预防OHSS 行全胚冷冻的临床研究[J].中国优生与遗传杂志，2012，20（9）：99-101.
[5] Nastri CO，Teixeira DM，Moroni RM，et al. Ovarian hyperstimulation syndrome：pathophysiology，staging，prediction and prevention [J]. Ultrasound Obstet Gynecol，2015，45（4）：523-534.
[6] Boothroyd C，Karia S，Andreadis N，et al. Consensus statement on prevention and detection of ovarian hyperstimulation syndrome [J]. Aust N Z J Obstet Gynaecol，2015，55（6）：41-47.
[7] Humaidan P，Quartarolo J，Papanikolaou EG. Preventing ovarian hyperstimulation syndrome：guidance for the clinician [J]. Fertil Steril，2010，94（2）：389-400.
[8] Peluso C，Fonseca FL，Gastaldo GG，et al. AMH and AMHR2 polymorphisms and AMH serum level can predict assisted reproduction outcomes：a cross-sectional study [J]. Cell Physiol Biochem，2015，35（4）：1401-1412.
[9] Stracquadanio M，Ciotta L，Palumbo MA，et al. Relationship between serum anti-Mullerian hormone and intrafollicular AMH levels in PCOS women [J]. Gynecol Endocrinol，2018，34（3）：223-228.
[10] Nouri K，Tempfer CB，Lenart C，et al. Predictive factors for recovery time in patients suffering from severe OHSS [J]. Reprod Biol Endocrinol，2014，12：59.
[11] Youssef MA，van Wely M，Hassan MA，et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles？A systematic review and meta-analysis [J]. Hum Ｒeprod Update，2010，16（5）：450-466.
[12] Taheripanah R，Vasef M，Zamaniyan M，et al. Comparison of Cabergoline and Quinagolide in prevention of severe ovarian hyperstimulation syndrome among patients undergoing intracytoplasmic sperm injection [J]. Int J Fertil Steril，2018，12（1）：1-5.
[13] Gurgan T，Demirol A，Guven S，et al. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome [J]. Fertil Steril，2011，96（1）：53-57.
[14] 徐蓓，靳镭.在高反应人群中如何预防OHSS[J].生殖医学杂志，2017，26（11）：1071-1074.
[15] 王子一，张元珍.OHSS的预防及治疗研究进展[J].药学进展，2016，35（1）：62-66.
[16] Lainas G，Kolibianakis E，Sfontouris I，et al. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase：an observational cohort study [J]. Reprod Biol Endocrinol，2012，10（1）：69.
[17] Griesinger G. Ovarian hyperstimulation syndrome prevention strategies：use of gonadotropin releasing hormone antagonists [J]. Semin Reprod Med，2010，28（6）：493-499.
[18] 吕雁，刘红英，游兰，等.卵巢子宫内膜异位囊肿在腹腔镜术前应用GnRH-a的临床疗效分析[J].疑难病杂志，2017，16（7）：702-705.
[19] Lainas GT，Kolibianakis EM，Sfontouris IA，et al. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS [J]. Hum Reprod，2013，28（7）：1929-1942.
[20] Lin YH，Huang MZ，Hwang JL，et al. Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels—a retrospective study [J]. J Assist Reprod Genet，2013，30（6）：753-759.
[21] 唐淮云.多环节管理模式预防体外受精-胚胎移植周期OHSS 发生的临床研究[J].中国妇幼保健，2016，31（2）：235-237.